Matches in Wikidata for { <http://www.wikidata.org/entity/Q80366081> ?p ?o ?g. }
Showing items 1 to 41 of
41
with 100 items per page.
- Q80366081 description "clinical trial" @default.
- Q80366081 description "ensayu clínicu" @default.
- Q80366081 description "klinisch onderzoek" @default.
- Q80366081 description "клінічне випробування" @default.
- Q80366081 name "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression" @default.
- Q80366081 name "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression" @default.
- Q80366081 type Item @default.
- Q80366081 label "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression" @default.
- Q80366081 label "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression" @default.
- Q80366081 prefLabel "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression" @default.
- Q80366081 prefLabel "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression" @default.
- Q80366081 P1132 Q80366081-632E6FE5-4DB7-4DCB-8792-603570EEDF1C @default.
- Q80366081 P1476 Q80366081-F4B1978F-7A27-4ACA-A980-06684D5E18C5 @default.
- Q80366081 P1813 Q80366081-E92B209E-56D9-460E-B4AE-9243315ABE06 @default.
- Q80366081 P2899 Q80366081-74B761C6-9937-424B-B259-BAF458300764 @default.
- Q80366081 P3098 Q80366081-27218F9F-07C2-422B-8473-B16507BBE5C5 @default.
- Q80366081 P31 Q80366081-CDFD4913-BC3C-4A1F-92E4-49CFFEAF5CB4 @default.
- Q80366081 P4844 Q80366081-4291C53F-9C5A-498F-8D41-C23C54394F3F @default.
- Q80366081 P4844 Q80366081-5F741F56-D026-4B82-8D7A-E7540156B627 @default.
- Q80366081 P4844 Q80366081-D15BEA4E-3684-4F75-B78F-D1DD8D3B7C3D @default.
- Q80366081 P4844 Q80366081-FC578E75-9D67-4285-BB9F-B753900E63ED @default.
- Q80366081 P580 Q80366081-3F263865-8EBD-46E7-8B79-8E277E1C793B @default.
- Q80366081 P582 Q80366081-CFADBBE6-50F9-442B-B141-C03D28221646 @default.
- Q80366081 P6099 Q80366081-24C5DD64-BD64-47F2-8441-BD3BD42D354C @default.
- Q80366081 P767 Q80366081-13CCD7B7-DAC2-492F-96CB-9B52C6AE0570 @default.
- Q80366081 P8363 Q80366081-8FFF108B-9E7A-4F53-99B6-6C5931B3D233 @default.
- Q80366081 P1132 "+430" @default.
- Q80366081 P1476 "MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Advanced High- Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression" @default.
- Q80366081 P1813 "MIRASOL" @default.
- Q80366081 P2899 "+18" @default.
- Q80366081 P3098 "NCT04209855" @default.
- Q80366081 P31 Q30612 @default.
- Q80366081 P4844 Q127060 @default.
- Q80366081 P4844 Q18936 @default.
- Q80366081 P4844 Q29004943 @default.
- Q80366081 P4844 Q423762 @default.
- Q80366081 P580 "2019-12-01T00:00:00Z" @default.
- Q80366081 P582 "2022-06-01T00:00:00Z" @default.
- Q80366081 P6099 Q42824827 @default.
- Q80366081 P767 Q5625184 @default.
- Q80366081 P8363 Q78089383 @default.